AR049671A1 - 2-aminoimidazoles sustituidos, procedimiento para su preparacion, su uso como medicamento o ayuda al diagnostico, y medicamento que los contiene - Google Patents
2-aminoimidazoles sustituidos, procedimiento para su preparacion, su uso como medicamento o ayuda al diagnostico, y medicamento que los contieneInfo
- Publication number
- AR049671A1 AR049671A1 ARP040100314A ARP040100314A AR049671A1 AR 049671 A1 AR049671 A1 AR 049671A1 AR P040100314 A ARP040100314 A AR P040100314A AR P040100314 A ARP040100314 A AR P040100314A AR 049671 A1 AR049671 A1 AR 049671A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- atoms
- carbon atoms
- carbon
- alkyl
- Prior art date
Links
- 238000003745 diagnosis Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 8
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000001153 fluoro group Chemical group F* 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 208000009304 Acute Kidney Injury Diseases 0.000 abstract 1
- -1 NR9R10 Chemical group 0.000 abstract 1
- 208000033626 Renal failure acute Diseases 0.000 abstract 1
- 206010041235 Snoring Diseases 0.000 abstract 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 201000011040 acute kidney failure Diseases 0.000 abstract 1
- 208000012998 acute renal failure Diseases 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 208000020832 chronic kidney disease Diseases 0.000 abstract 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 150000002431 hydrogen Chemical class 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000002859 sleep apnea Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/44—Nitrogen atoms not forming part of a nitro radical
- C07D233/50—Nitrogen atoms not forming part of a nitro radical with carbocyclic radicals directly attached to said nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Toxicology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Se refiere a compuestos que son utiles en la prevencion y tratamiento de diversos desordenes. Así, los compuestos se pueden emplear, entre otros, para desordenes renales tales como fallo renal agudo o cronico, para desordenes de la funcion biliar, para desordenes respiratorios tales como ronquido o apneas del sueno o para el ataque cerebral. Reivindicacion 1: Un compuesto de la formula (1), en la que los significados son: R1 y R2 son junto con los dos átomos de carbono a los que están enlazados, un anillo de carbonos de cinco, seis, siete u ocho miembros que comprende uno o dos dobles enlaces; en donde el anillo está sustituido o está sustituido con 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 o 12 átomos de F y/o con uno o dos radicales del grupo de OH, NR9R10, alquilo con 1, 2, 3 o 4 átomos de carbono, CN, CF3 o alcoxi con 1, 2, 3 o 4 átomos de carbono; R9 y R10 independientemente uno del otro, H o alquilo con 1, 2, 3 o 4 átomos de carbono; o R1 y R2 son independientemente uno del otro, H, alquilo con 1, 2, 3 o 4 átomos de carbono, CN o fenilo; en donde las cadenas de carbonos no están sustituidas o están sustituidas independientemente una de otra con 1, 2, 3, 4, 5, 6, 7, 8 o 9 átomos de F; en donde R1 y R2 no corresponden ambos simultáneamente a hidrogeno; R3, R4, R5, R6 y R7 son independientemente uno de otro, H, F, Cl, Br, I, alquilo con 1, 2, 3 o 4 átomos de carbono, o alcoxi con 1, 2, 3 o 4 átomos de carbono; en donde las cadenas de carbonos no están sustituidas o están sustituidas independientemente una de otra con 1, 2, 3, 4, 5, 6, 7, 8 o 9 átomos de F; en donde R3 y R7 no corresponden ambos simultáneamente a hidrogeno; R8 es H, alquilo con 1, 2, 3 o 4 átomos de carbono o cicloalquilo con 3, 4 o 5 átomos de carbono; en donde las cadenas de carbonos o radicales cicloalquilo no están sustituidos o están sustituios con 1, 2, 3, 4, 5, 6, 7, 8 o átomos de F; y sus sales y sales de ácido trifluoroacético aceptables farmacéuticamente; en donde R1 y R2 no son ambos simultáneamente metilo cuando R3 es Cl y R4, R5, R6, R7 y R8 son hidrogeno, en donde se excluye (2,6-diclofenil)-(4-metil-1H-imidazol-2-il)-amin.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10304374A DE10304374A1 (de) | 2003-02-04 | 2003-02-04 | Neue substituierte 2-Aminoimidazole, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR049671A1 true AR049671A1 (es) | 2006-08-30 |
Family
ID=32667986
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040100314A AR049671A1 (es) | 2003-02-04 | 2004-02-02 | 2-aminoimidazoles sustituidos, procedimiento para su preparacion, su uso como medicamento o ayuda al diagnostico, y medicamento que los contiene |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US7442717B2 (es) |
| EP (2) | EP1857445B1 (es) |
| JP (2) | JP4630269B2 (es) |
| AR (1) | AR049671A1 (es) |
| AT (1) | ATE375982T1 (es) |
| AU (1) | AU2004208870A1 (es) |
| BR (1) | BRPI0407212A (es) |
| CA (1) | CA2514028A1 (es) |
| DE (3) | DE10304374A1 (es) |
| MX (1) | MXPA05007968A (es) |
| PE (1) | PE20040943A1 (es) |
| TW (1) | TW200508206A (es) |
| WO (1) | WO2004069806A2 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050054705A1 (en) * | 2003-02-04 | 2005-03-10 | Aventis Pharma Deutschland Gmbh | N-substituted (benzoimidazol-2-yl) phenylamines, process for their preparation, their use as medicament or diagnostic aid, and medicament comprising them |
| WO2005107470A2 (en) * | 2004-04-29 | 2005-11-17 | University Of Florida Research Foundation, Inc. | Use of carbonic anhydrase inhibitors for insect control and malaria treatment |
| US7592362B2 (en) * | 2006-01-19 | 2009-09-22 | Pfizer Limited | Substituted imidazoles |
| US20120088737A2 (en) * | 2009-10-02 | 2012-04-12 | Ajinomoto Co., Inc | Novel acyl guanidine derivatives |
| EP3173408B1 (en) | 2014-07-25 | 2018-11-21 | Taisho Pharmaceutical Co., Ltd. | Phenyl tetrahydroisoquinoline compound substituted with heteroaryl |
| CN109422695B (zh) * | 2017-08-28 | 2022-03-18 | 扬子江药业集团有限公司 | 一种盐酸苯达莫司汀粗品的制备方法 |
| CN118619883B (zh) * | 2024-05-24 | 2025-11-11 | 河北圣泰材料股份有限公司 | 一种4,5-二氰基-2-三氟甲基咪唑锂的制备方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3459763A (en) * | 1966-01-25 | 1969-08-05 | Geigy Chem Corp | Certain amino imidazole derivatives |
| EP0008150B1 (en) * | 1978-08-16 | 1982-04-28 | Farmos-Yhtyma Oy | 2,6-dichlorophenyl-substituted amino-imidazole derivatives, processes of preparing such derivatives and pharmaceutical preparations comprising said derivatives |
| US4275072A (en) * | 1978-08-16 | 1981-06-23 | Farmos Group, Ltd. | 2,6-Dichlorophenyl-substituted amino-imidazole derivatives and use as hypertensive agents |
| US4868183A (en) * | 1986-07-21 | 1989-09-19 | Otsuka Pharmaceutical Factory, Inc. | N-pyrazinyl substituted P-aminophenols |
| GR900100380A (el) * | 1989-05-20 | 1991-10-10 | Fisons Plc | Μέ?οδος παρασκευής αντι-φλεγμονωδών παραγώγων αμινοφενόλης. |
| EP0741709B1 (en) * | 1994-01-24 | 2001-07-25 | Allergan Sales, Inc. | Aromatic 2-amino-imidazole derivatives as alpha-2a adrenoceptor agonists |
| DE19633966A1 (de) | 1996-08-22 | 1998-02-26 | Hoechst Ag | Phenylsubstituierte Alkenylcarbonsäure-guanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| DE19945302A1 (de) | 1999-09-22 | 2001-03-29 | Merck Patent Gmbh | Biphenylderivate als NHE-3-Inhibitoren |
| WO2001021160A2 (en) * | 1999-09-23 | 2001-03-29 | Axxima Pharmaceuticals Aktiengesellschaft | Carboxymide and aniline derivatives as selective inhibitors of pathogens |
| DE19960204A1 (de) * | 1999-12-14 | 2001-06-28 | Aventis Pharma Gmbh | Substituierte Norlbornylamino-Derivate, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| DE10015248A1 (de) | 2000-03-28 | 2001-10-04 | Merck Patent Gmbh | Bisamidino-Verbindungen als NHE-3 Inhibitoren |
| DE10019062A1 (de) | 2000-04-18 | 2001-10-25 | Merck Patent Gmbh | 2-Guanidino-4-aryl-chinazoline als NHE-3 Inhibitoren |
| DE10043667A1 (de) | 2000-09-05 | 2002-03-14 | Merck Patent Gmbh | 2-Guanidino-4-aryl-chinazoline |
| EP1578341A4 (en) * | 2000-10-11 | 2005-09-28 | Tularik Inc | MODULATION OF THE CCR4 FUNCTION |
| DE10060292A1 (de) * | 2000-12-05 | 2002-06-20 | Aventis Pharma Gmbh | Verwendung substituierter Benzimidazole zur Herstellung eines Medikaments zur Behandlung von Krankheiten, welche durch Inhibierung des Na+/H+-Austauschers beeinflusst werden können und sie enthaltendes Medikament |
| US20030187045A1 (en) * | 2001-12-21 | 2003-10-02 | Uwe Heinelt | Substituted imidazolidines, process for their preparation, and their use as a medicament or diagnostic |
| US7049333B2 (en) * | 2002-06-04 | 2006-05-23 | Sanofi-Aventis Deutschland Gmbh | Substituted thiophenes: compositions, processes of making, and uses in disease treatment and diagnosis |
-
2003
- 2003-02-04 DE DE10304374A patent/DE10304374A1/de not_active Withdrawn
-
2004
- 2004-01-20 EP EP07014956A patent/EP1857445B1/de not_active Expired - Lifetime
- 2004-01-20 AT AT04703371T patent/ATE375982T1/de not_active IP Right Cessation
- 2004-01-20 JP JP2006501561A patent/JP4630269B2/ja not_active Expired - Fee Related
- 2004-01-20 DE DE502004009771T patent/DE502004009771D1/de not_active Expired - Lifetime
- 2004-01-20 BR BR0407212-0A patent/BRPI0407212A/pt not_active IP Right Cessation
- 2004-01-20 DE DE502004005260T patent/DE502004005260D1/de not_active Expired - Lifetime
- 2004-01-20 AU AU2004208870A patent/AU2004208870A1/en not_active Abandoned
- 2004-01-20 CA CA002514028A patent/CA2514028A1/en not_active Abandoned
- 2004-01-20 WO PCT/EP2004/000394 patent/WO2004069806A2/de not_active Ceased
- 2004-01-20 MX MXPA05007968A patent/MXPA05007968A/es unknown
- 2004-01-20 EP EP04703371A patent/EP1592669B1/de not_active Expired - Lifetime
- 2004-01-28 PE PE2004000108A patent/PE20040943A1/es not_active Application Discontinuation
- 2004-02-02 TW TW093102254A patent/TW200508206A/zh unknown
- 2004-02-02 AR ARP040100314A patent/AR049671A1/es unknown
- 2004-02-03 US US10/771,185 patent/US7442717B2/en not_active Expired - Fee Related
-
2008
- 2008-07-14 US US12/172,380 patent/US20080275098A1/en not_active Abandoned
-
2010
- 2010-09-02 JP JP2010196422A patent/JP2011016825A/ja not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA05007968A (es) | 2005-09-20 |
| ATE375982T1 (de) | 2007-11-15 |
| EP1592669A2 (de) | 2005-11-09 |
| JP2006516576A (ja) | 2006-07-06 |
| AU2004208870A1 (en) | 2004-08-19 |
| DE10304374A1 (de) | 2004-08-05 |
| WO2004069806A2 (de) | 2004-08-19 |
| US7442717B2 (en) | 2008-10-28 |
| EP1857445A3 (de) | 2007-12-19 |
| PE20040943A1 (es) | 2005-02-07 |
| WO2004069806A3 (de) | 2004-10-28 |
| DE502004009771D1 (de) | 2009-08-27 |
| EP1857445B1 (de) | 2009-07-15 |
| CA2514028A1 (en) | 2004-08-19 |
| JP2011016825A (ja) | 2011-01-27 |
| EP1857445A2 (de) | 2007-11-21 |
| EP1592669B1 (de) | 2007-10-17 |
| BRPI0407212A (pt) | 2006-01-24 |
| US20080275098A1 (en) | 2008-11-06 |
| DE502004005260D1 (de) | 2007-11-29 |
| TW200508206A (en) | 2005-03-01 |
| US20040259927A1 (en) | 2004-12-23 |
| JP4630269B2 (ja) | 2011-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20070218A1 (es) | COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA | |
| ES2216266T3 (es) | 1-fenil-4-bencilpiperazinas: ligandos especificos del subtipo receptorde dopamina d4. | |
| CY1115058T1 (el) | Παραγωγα 1,2,3- τριαζολης για χρηση ως αναστολεις στεατοϋλο-coa δεσατουρασης | |
| AR083849A1 (es) | Antagonistas de mdm2 de espiro-oxindol | |
| SE0104334D0 (sv) | Therapeutic agents | |
| RU2014121090A (ru) | Модуляторы рецептора нмда и их применение | |
| AR033306A1 (es) | Compuestos | |
| ECSP045483A (es) | Derivados de heteroarilamida benzocondensada de tienopiridinas útiles como agentes terapéuticos, composiciones farmacéuticas que incluyen a los mismos, y métodos para su uso | |
| AR048934A1 (es) | Morfolinas | |
| MX2010003224A (es) | Derivados de biaril sulfonamida. | |
| AR080803A1 (es) | Derivados de 3,4-dihidro-1h-benzo[b][1,6]naftiridina, composiciones farmaceuticas que los contiene, procedimiento para prepararlos e intermediarios del mismo, y uso de los compuestos en el tratamiento de canceres y enfermedades autoinmunes e inflamatorias. | |
| ECSP055867A (es) | Derivados de pirrolopirimidina | |
| EA200901379A1 (ru) | Производные никотиновой кислоты как модуляторы метаботропных глутаматных рецепторов 5 подтипа | |
| MX2010001080A (es) | Pirrolidin-aril-eteres como antagonistas de receptor de nk3. | |
| EA200802173A1 (ru) | Производные терфенила для лечения болезни альцгеймера | |
| WO2006086705B1 (en) | Substituted bis aryl and heteroaryl compounds as selective 5ht2a antagonists | |
| EA201370184A1 (ru) | Гетероарильные производные | |
| AR071592A1 (es) | Fenoxibenzamidas sustituidas | |
| AR049671A1 (es) | 2-aminoimidazoles sustituidos, procedimiento para su preparacion, su uso como medicamento o ayuda al diagnostico, y medicamento que los contiene | |
| WO2011056744A4 (en) | IRE-1 α INHIBITORS | |
| MX2009010727A (es) | Heterociclos como antagonistas de orexina. | |
| TW200833697A (en) | Spiro-piperidine derivatives | |
| PE20001339A1 (es) | Uso de derivados del acido 4-biarilbutirico y 5-biarilpentanoico sustituidos como inhibidores de la metaloproteasa de matriz para el tratamiento de enfermedades respiratorias | |
| AR035311A1 (es) | Derivados de acido hidroxamico que contienen alquinilo, como inhibidores de las metalloproteinasas de matriz y de la tace, composicion farmaceutica y el uso de los mismos para la manufactura de un medicamento | |
| IL206615A (en) | The History of Pipridine Sulfonamide, the Process for Preparing it, Medicines Containing It, and Their Use in the Preparation of Medication for Treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |